Defective hemostasis in @entity447 @entity1 with @entity2801 inhibitors results in a dramatic decrease in @entity556 generation forming unstable fibrin clots that are susceptible to fibrinolyisis. In this study we tested whether the combination of plasma derived activated prothrombin complex concentrate (pd-aPCC) with @entity927 ( @entity928 ) may improve fibrin clot stability in @entity2801 inhibitor plasma. A microplate assay for clot lysis time was used to assess clot stability in @entity2801 inhibitor plasma. The effect of pd-aPCC on clot stability was first tested using the commercial @entity2801 inhibitor plasma. @entity928 (5 ~ 10 mg mL     ) increased clot lysis time, but pd-aPCC (0.25 ~ 1.0 U mL     ) had no effect on it. The combination of pd-aPCC and @entity928 significantly increased clot lysis time compared with @entity928 alone. The effect appeared to be limited to fibrin clot resistance to fibrinolysis, as @entity928 was found to have no effect on @entity556 generation induced by pd-aPCC. The effect of pd-aPCC and @entity928 on clot stability was then tested and verified in plasma samples from ten @entity1 with severe @entity447 and inhibitors. The combination of @entity928 (10 mg mL     ) and pd-aPCC (0.5 U mL     ) significantly increased clot lysis time compared to @entity928 alone. Our results suggest that the combination of pd-aPCC with @entity928 improves clot stability in @entity2801 inhibitor plasma without additional increases in @entity556 generation.

Stabilization of fibrin clots by activated prothrombin complex concentrate and XXXX in @entity2801 inhibitor plasma.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2801 :: ('2157', 'Gene') :: ['FVIII'] @entity556 :: ('2147', 'Gene') :: ['thrombin'] @entity447 :: ('MESH:D006467', 'Disease') :: ['haemophilia', 'haemophilia A'] @entity928 :: ('CHEBI:36088', 'Chemical') :: ['TXA'] @entity927 :: ('MESH:D014148', 'Chemical') :: ['tranexamic acid']
@entity927 :: (MESH:D014148,Chemical) :: ['tranexamic acid']
